Allarity Therapeutics and Detsamma Investments, which trades as FivepHusion, have announced a clinical collaboration agreement. Allarity is a clinical-stage pharmaceutical company developing novel oncology therapeutics and drug-specific DRP companion diagnostics for personalised cancer care. FivepHusion is an advanced clinical-stage biotechnology company developing Deflexifol, an optimised all-in-one formulation of the chemotherapeutic agent 5-fluorouracil (5FU) and its biomodulator leucovorin (LV).

https://www.miragenews.com/allarity-fivephusion-partner-to-develop-1058275/

#miragenews